DJ Hardman & Co: Q&A on Shield Therapeutics (STX): Upside potential is enormous
Hardman & Co Research Hardman & Co: Q&A on Shield Therapeutics (STX): Upside potential is enormous 12-Aug-2022 / 11:45 GMT/BST
-----------------------------------------------------------------------------------------------------------------------
Hardman & Co Video | Analyst interview
Shield Therapeutics (STX): Upside potential is enormous
Shield Therapeutics (STX) is the topic of conversation when Martin Hall joins DirectorsTalk Interviews.
Despite launching a drug into the US market, Shield has performed really badly over
the past 12 months, Martin explains what happened, shares his thoughts on the considerable progress made, implications for the full year, why the share price is falling, investment capital and the investment opportunity.
Shield Therapeutics is a specialty pharmaceutical company focused on the development and commercialisation of late stage, hospital focused pharmaceuticals.
Listen to the interview here:
If you are interested in meeting the company, you can register your interest here
Download our latest report on STX, here
To contact us:
Hardman & Co Contact:
1 Frederick's Place
Martin Hall
London mh@hardmanandco.com
EC2R 8AE
+44 (0)203 693 7075
www.hardmanandco.com
Follow us on Twitter @HardmanandCo
Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.
About Hardman & Co: Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Attention is drawn to the important disclaimers at the end of the report.
-----------------------------------------------------------------------------------------------------------------------
Dissemination of a CORPORATE NEWS, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.
-----------------------------------------------------------------------------------------------------------------------
End of Announcement - EQS News Service
1419419 12-Aug-2022
Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1419419&application_name=news
(END) Dow Jones Newswires
August 12, 2022 06:45 ET (10:45 GMT)
